Bioasis Technologies (FRA:107) Debt-to-Asset : 1.26 (As of Nov. 2022)

View and export this data going back to 2017. Start your Free Trial

What is Bioasis Technologies Debt-to-Asset?

Bioasis Technologies's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Nov. 2022 was €1.09 Mil. Bioasis Technologies's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Nov. 2022 was €0.52 Mil. Bioasis Technologies's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Nov. 2022 was €1.29 Mil. Bioasis Technologies's debt to asset for the quarter that ended in Nov. 2022 was 1.26.

Bioasis Technologies Debt-to-Asset Historical Data

The historical data trend for Bioasis Technologies's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioasis Technologies Debt-to-Asset Chart

Bioasis Technologies Annual Data

Trend

Feb13

Feb14

Feb15

Feb16

Feb17

Feb18

Feb19

Feb20

Feb21

Feb22

Debt-to-Asset

Get a 7-Day Free Trial

1.07

0.04

0.84

Bioasis Technologies Quarterly Data
	Feb18	May18	Aug18	Nov18	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22
Debt-to-Asset	Get a 7-Day Free Trial															0.67	0.84	1.38	0.86	1.26

Competitive Comparison of Bioasis Technologies's Debt-to-Asset

For the Biotechnology subindustry, Bioasis Technologies's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bioasis Technologies's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bioasis Technologies's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Bioasis Technologies's Debt-to-Asset falls into.

Bioasis Technologies Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Bioasis Technologies's Debt-to-Asset for the fiscal year that ended in Feb. 2022 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(1.04	+	0.279)	/	1.571
	=	0.84

Bioasis Technologies's Debt-to-Asset for the quarter that ended in Nov. 2022 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(1.093	+	0.52)	/	1.285
	=	1.26

Bioasis Technologies (FRA:107) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Bioasis Technologies Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Bioasis Technologies's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Bioasis Technologies (FRA:107) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bioasis Technologies Inc (FRA:107) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

157 Church Street, 19th Floor, New Haven, CT, USA, 06510

Website

https://www.bioasis.us

Bioasis Technologies Inc is a development stage biopharmaceutical company. It is engaged in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. The company has worked on a blood-brain barrier program and studies disorders in the brain. The company's xB3 program describes its proprietary carrier, for the delivery of therapeutics across the blood-brain barrier and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases. The company's in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.

Bioasis Technologies (FRA:107) Headlines

No Headlines